Markus Warmuth, M.D.
Markus focuses on the formation of new companies. Before joining Third Rock, Markus served as president and chief executive officer of H3 Biomedicine and was responsible for the overall scientific and business direction of the company. Markus joined H3 shortly after inception and since built it into a clinical stage biotech company, pursuing data science driven drug discovery. Prior to joining H3 in 2011, Markus was head of oncology drug discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site where he led a significant portion of NIBR’s global oncology drug discovery portfolio. From 2002 to April 2008, he served as director of kinase biology, head of the oncology pharmacology program and as a member of the research and drug discovery steering committee for the Genomics Institute of the Novartis Research Foundation (GNF), San Diego. While at GNF and NIBR, he led groups involved in developing now approved drugs such as Ceritinib and Ribociclib. Markus has served on the scientific advisory board of Keystone Symposia and currently serves on the scientific review board of the Starr Cancer Consortium.